<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440725</url>
  </required_header>
  <id_info>
    <org_study_id>PRP-RICE</org_study_id>
    <secondary_id>ISCIII; Spain</secondary_id>
    <nct_id>NCT01440725</nct_id>
  </id_info>
  <brief_title>Efficacy of Platelet Rich Plasma for Treatment of Muscle Rupture With Haematoma</brief_title>
  <acronym>PRP-RICE</acronym>
  <official_title>Multicenter Double Blind, With Evaluator Blinding, Parallel, Randomized Clinical Trial, to Assess the Efficacy of Platelet Rich Plasma for Treatment of Muscle Rupture With Haematoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Terapia Regenerativa Tissular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asociacion Colaboracion Cochrane Iberoamericana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Terapia Regenerativa Tissular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, simple blind, masking of outcomes assessors, parallel, randomised
      clinical trial in patient with muscle rupture and with hematoma production. The main
      hypothesis is that infiltration in the area of muscle injury in autologous platelet-rich
      plasma (PRP)improves muscle regeneration and repair by shortening the time to complete
      recovery.

      The main objective is to evaluate the PRP for healing muscular lesions 'tennis leg' type or
      distal rectus femoral. The secondary objectives are: to evaluate the risk of lesion
      recurrence; to evaluate the quality of lesion recovery process and evaluate intervention's
      safety.

      Experimental treatment will be the administration of PRP autologous (4-8 cc in a unique dose)
      by muscular infiltration en the empty space generated after the hematoma evacuation. Control
      treatment will be hematoma evacuation. Both treatment groups will use compressive bandage and
      they will recommend rest, extremity elevation, local ice and lately physiotherapy.

      Size sample: 76 patients (38 in each group)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to complete recover of muscular lesions</measure>
    <time_frame>weekely assessment during 8 weeks</time_frame>
    <description>The complete recovering will be when the patient does his habitual activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of muscular lesion recurrence.</measure>
    <time_frame>During all study (one year of follow-up)</time_frame>
    <description>Percentage of patients with muscular lesion recurrence.
Muscular lesion recurrence will be considered if there are symptoms and a lesion gap by ultra sound scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of healing</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of patients with the healed lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of the regenerated area</measure>
    <time_frame>at 8 week</time_frame>
    <description>By ultrasonography, the characteristics of the wound will be quantified (size, fibrosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>12 months</time_frame>
    <description>The pain will be measured by a VAS each week, the first 8 weeks of the study and, at 6 and 12 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects to treatments</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse effects will be assessed each week, the first 8 weeks of the study and, at 6 and 12 month.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Muscle Injuries</condition>
  <arm_group>
    <arm_group_label>PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 4-8cc of autologous Platelet-rich plasma (PRP)into the muscle wound after the evacuation of the haematoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacuation of haematoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evacuation of the hematoma, and simulation of the administration of PRP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Platelet-rich plasma (PRP)</intervention_name>
    <description>4-8cc, a single dose</description>
    <arm_group_label>PRP</arm_group_label>
    <other_name>Platelet-rich plasma</other_name>
    <other_name>Growth factors from platelet-rich plasma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Evacuation of haematoma</intervention_name>
    <description>Evacuation of the haematoma, a single procedure</description>
    <arm_group_label>Evacuation of haematoma</arm_group_label>
    <other_name>Drainage of haematoma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over 18 years

          -  Lesion with haematoma at the Gastrocnemius muscle or the lower portion of the rectus
             femoral muscle

          -  Acceptance to participate at the clinical trial

          -  Not indicated the surgical treatment of the muscle injury

        Exclusion criteria

          -  Patients who do not meet the inclusion criteria

          -  History of bleeding disorders

          -  Inability to follow-up the patient

          -  The use of corticosteroids, acetylsalicylic acid(Aspirin ®) and nonsteroidal
             antiinflammatory drugs during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martínez Zapata, Mª José</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Cochrane Iberoamericano. Servicio de Epidemiología Clínica y Salud Pública. IIB Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Orozco Delclòs, LLuís</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Teràpia Regenerativa i Tissular. Centro Médico Teknon. Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Cochrane Iberoamericano</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>January 8, 2013</last_update_submitted>
  <last_update_submitted_qc>January 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>muscle</keyword>
  <keyword>injuries</keyword>
  <keyword>platelet-rich plasma</keyword>
  <keyword>autologous</keyword>
  <keyword>haematoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

